title: Safety of rapid-acting insulin analogs versus regular human insulin.
abstract: Insulin is the most effective treatment for both type 1 and type 2 diabetes mellitus. There are several differences in the safety profiles of each type of insulin, including rapid-acting insulin analogs and regular human insulin. The pharmacokinetic and pharmacodynamic properties of those insulin types also differ, as do their safety parameters. Treatment with rapid-acting analogs results in less hypoglycemia overall and decreased frequency of both severe and nocturnal hypoglycemia. In addition, the more rapid onset and shorter duration of action of rapid-acting insulin analogs are associated with greater control of postprandial glucose than regular human insulin. This review will describe the similarities and differences between the safety profiles of rapid-acting insulin analogs.
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, 38163, USA. akitabch@uthsc.edu
authors.forename: Abbas E
authors.initials: AE
authors.lastname: Kitabchi
authors.forename: Aidar R
authors.initials: AR
authors.lastname: Gosmanov
mesh_terms: D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D007003:Hypoglycemia / Q000139:chemically induced; D061266:Insulin, Short-Acting / Q000009:adverse effects* / Q000493:pharmacokinetics
chemical_list: D061266:Insulin, Short-Acting